Metastatic Castration-Resistant Prostate Cancer
Conditions
Brief summary
Overall Survival (OS), Radiographic progression-free survival (rPFS)
Detailed description
Time to first subsequent therapy (TFST), Objective response rate (ORR), Duration of Response (DOR), Time to pain progression (TTPP), Time to prostate-specific antigen (PSA) progression, PSA response rate, Time to first symptomatic skeletal-related events (SSRE), Number of Participants Who Experience One or More Adverse Events (AEs), Number of Participants Who Discontinue Study Treatment Due to an AE
Interventions
Sponsors
Merck Sharp & Dohme LLC
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Survival (OS), Radiographic progression-free survival (rPFS) | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to first subsequent therapy (TFST), Objective response rate (ORR), Duration of Response (DOR), Time to pain progression (TTPP), Time to prostate-specific antigen (PSA) progression, PSA response rate, Time to first symptomatic skeletal-related events (SSRE), Number of Participants Who Experience One or More Adverse Events (AEs), Number of Participants Who Discontinue Study Treatment Due to an AE | — |
Countries
Austria, Czechia, Denmark, France, Germany, Greece, Ireland, Italy, Netherlands, Norway, Poland, Spain, Sweden
Outcome results
None listed